Clinuvel Pharmaceuticals Limited

ASX CUV.AX

Clinuvel Pharmaceuticals Limited Gross Profit Margin for the year ending June 30, 2024: 91.23%

Clinuvel Pharmaceuticals Limited Gross Profit Margin is 91.23% for the year ending June 30, 2024, a 41.24% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Clinuvel Pharmaceuticals Limited Gross Profit Margin for the year ending June 30, 2023 was 64.59%, a -8.94% change year over year.
Clinuvel Pharmaceuticals Limited Gross Profit Margin for the year ending June 30, 2022 was 70.93%, a -3.34% change year over year.
Clinuvel Pharmaceuticals Limited Gross Profit Margin for the year ending June 30, 2021 was 73.38%, a 29.66% change year over year.
Clinuvel Pharmaceuticals Limited Gross Profit Margin for the year ending June 30, 2020 was 56.60%, a -42.58% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

ASX: CUV.AX

Clinuvel Pharmaceuticals Limited

CEO	Dr. Philippe Jacques Wolgen M.B.A., M.D.
IPO Date	Feb. 11, 2001
Location	Australia
Headquarters	535 Bourke Street
Employees	16
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years